Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on Semaglutide and Low-Calorie Diet for Weight Loss in Patients with New-Onset Idiopathic Intracranial Hypertension

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition called Idiopathic Intracranial Hypertension (IIH), which is a disorder characterized by increased pressure around the brain without a clear cause. The study is investigating the effects of a medication called Semaglutide, which is also known by the code name NNC0113-0217, and a very low-calorie diet on body weight and brain pressure in patients with newly diagnosed IIH. The medication is administered as a solution for injection and is available in different doses under the brand names Ozempic and Wegovy.

The purpose of the study is to explore how Semaglutide and dietary changes can help manage weight and reduce brain pressure in individuals with IIH. Participants will receive either the medication or a placebo, along with dietary guidance. The study will last for several months, during which participants will have regular check-ups to monitor changes in their condition, including body weight and brain pressure. The study aims to provide insights into the effectiveness of this combined treatment approach compared to standard management by a dietician.

Throughout the study, participants will undergo various assessments to track their progress. These assessments will include measuring changes in brain pressure and body weight, as well as evaluating the degree of swelling in the optic nerve, which is known as papilledema. Other evaluations will include visual field tests, imaging of the eye, and assessments of headache frequency and intensity. The study will also monitor the overall quality of life and any side effects experienced by participants. The findings from this study could potentially lead to improved treatment options for individuals with Idiopathic Intracranial Hypertension.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment will be conducted to confirm eligibility. This includes verifying the diagnosis of idiopathic intracranial hypertension and ensuring all inclusion criteria are met.

    The assessment will involve a review of medical history, a physical examination, and specific tests to measure intracranial pressure and body weight.

  2. Step 2

    Medication administration

    Participants will receive the medication semaglutide through a subcutaneous injection. The dosage will vary depending on the specific product used: Ozempic (0.25 mg, 0.5 mg, or 1 mg) or Wegovy (1.7 mg or 2.4 mg).

    Injections will be administered once a week for the duration of the study.

  3. Step 3

    Dietary program

    Participants will follow a very low-calorie diet as part of the study. This diet is designed to assist with weight loss and will be monitored by a dietician.

    Regular consultations with the dietician will be scheduled to ensure adherence to the dietary program and to provide support.

  4. Step 4

    Follow-up assessments

    Follow-up assessments will occur at 8 weeks and 10 months to evaluate changes in intracranial pressure and body weight.

    Additional evaluations will include eye examinations, headache assessments, and quality of life questionnaires.

  5. Step 5

    Final evaluation

    At the end of the study period, a final evaluation will be conducted to assess the overall impact of the treatment on intracranial pressure, body weight, and other health parameters.

    Participants will be informed of the study results and any further recommendations for their health management.

Who can join the trial?

5 criteria

  • Have a new diagnosis of Idiopathic Intracranial Hypertension with swelling of the optic nerve (called papilledema) and a lumbar opening pressure of 25 cm or more of cerebrospinal fluid.
  • Be a female aged between 18 and 65 years.
  • Have a Body Mass Index (BMI) of 27 or higher. BMI is a measure of body fat based on height and weight.
  • Provide written informed consent, which means you agree to participate in the study after understanding all the details.
  • Currently use or agree to start using contraceptive methods with a failure rate of less than 1% during the study if you are in group A. This includes using methods like hormonal contraceptives (such as pills, patches, vaginal rings, or injections), intrauterine devices (IUDs), having a partner who is permanently sterilized, or practicing credible sexual abstinence for religious or cultural reasons. This should continue for at least 2 months after stopping the study medication, Semaglutide.

Who cannot join the trial?

4 criteria

  • Patients who are not female cannot participate in the study.
  • Patients who are not within the specified age range cannot participate in the study.
  • Patients with conditions other than Idiopathic Intracranial Hypertension cannot participate in the study.
  • Patients who are part of a vulnerable population cannot participate in the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Semaglutide is a medication that helps with weight loss by mimicking a hormone in your body that regulates appetite. It makes you feel full, so you eat less and lose weight. In this trial, it is being used to help reduce body weight and lower pressure inside the skull in patients with a condition called idiopathic intracranial hypertension.

What is already known about the treatment

Semaglutide – Semaglutide is administered as an injection under the skin, typically once a week. It is currently being studied for its potential benefits in treating idiopathic intracranial hypertension, a condition characterized by increased pressure around the brain. The main therapeutic indication for Semaglutide in this trial is to assist with rapid weight loss, which may help reduce intracranial pressure. At the molecular level, Semaglutide works by mimicking a hormone called GLP-1, which helps regulate appetite and insulin levels, leading to weight loss. It is classified as a GLP-1 receptor agonist in pharmacology.

Investigated diseases

Idiopathic Intracranial Hypertension – Idiopathic Intracranial Hypertension is a condition characterized by increased pressure around the brain without a detectable cause. It often presents with symptoms such as headaches, vision problems, and ringing in the ears. The condition is more common in women, particularly those who are overweight. As the disease progresses, it can lead to swelling of the optic nerve, known as papilledema, which may cause visual disturbances. The increased pressure can also result in frequent headaches and other neurological symptoms. Over time, if not managed, it can lead to persistent vision problems.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-517120-19-02Estimated enrolment50 patientsSponsorRegion Hovedstaden

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.